Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray Sells 268,432 Shares of Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray sold 268,432 shares of the firm’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total value of $1,076,412.32. Following the completion of the sale, the chief financial officer now owns 1,032,754 shares of the company’s stock, valued at approximately $4,141,343.54. This trade represents a 20.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Checkpoint Therapeutics Stock Up 11.3 %

Checkpoint Therapeutics stock opened at $3.75 on Friday. The stock has a market cap of $183.12 million, a price-to-earnings ratio of -2.04 and a beta of 1.34. Checkpoint Therapeutics, Inc. has a 12-month low of $1.38 and a 12-month high of $4.50. The business’s 50-day simple moving average is $3.57 and its 200 day simple moving average is $2.70.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). As a group, sell-side analysts expect that Checkpoint Therapeutics, Inc. will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CKPT. Choreo LLC increased its holdings in Checkpoint Therapeutics by 12.2% in the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after purchasing an additional 7,080 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Checkpoint Therapeutics in the 2nd quarter valued at about $34,000. B. Riley Wealth Advisors Inc. raised its position in shares of Checkpoint Therapeutics by 366.3% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock valued at $493,000 after acquiring an additional 180,050 shares during the period. PVG Asset Management Corp bought a new position in Checkpoint Therapeutics during the 2nd quarter worth approximately $295,000. Finally, Magnus Financial Group LLC grew its holdings in Checkpoint Therapeutics by 12.9% during the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after purchasing an additional 4,000 shares during the period. Institutional investors and hedge funds own 22.00% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on CKPT shares. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday, December 16th. Lake Street Capital raised their price target on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a report on Monday, December 16th.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.